Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Boston Scientific (NYSE: BSX) plans to participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, featuring a 35-minute Q&A session with its CEO Mike Mahoney and CMO Kenneth Stein at approximately 8:00 a.m. ET.
The company will also host a third quarter 2026 earnings conference call on October 28, 2026 at 8:00 a.m. ET, led by Mike Mahoney and CFO Jon Monson, following a same-day earnings news release. Live webcasts and replays for both events will be available on the Boston Scientific investor relations website about one hour after each event concludes.
Penumbra (NYSE: PEN) reported second-quarter 2026 revenue of $390.0 million, up 14.9% year over year. Thrombectomy revenue was $259.0 million (+12.5%), while embolization and access revenue reached $131.1 million (+20.0%). U.S. revenue grew 17.1% to $305.4 million; international revenue increased 7.6% to $84.6 million.
Gross margin was 67.9%, up 1.9 percentage points. Operating expenses were $223.9 million, including $6.9 million of acquisition-related costs tied to the pending acquisition by Boston Scientific (NYSE: BSX). Income from operations was $41.0 million, and net income was $34.8 million, or $0.88 diluted EPS. Penumbra will not provide 2026 guidance or host a Q2 earnings call due to the pending transaction.
Boston Scientific (NYSE: BSX) reported Q2 2026 net sales of $5.442 billion, up 7.5% reported and 7.0% operational and organic versus Q2 2025. GAAP EPS was $0.61 (vs. $0.53), and adjusted EPS reached $0.86, above the $0.82–$0.84 guidance range.
MedSurg sales grew 5.9% and Cardiovascular 8.3% reported. By region, U.S. rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4% reported. Operating income increased to $1.178 billion from $819 million, while litigation-related net charges were $76 million.
The company completed a $2 billion accelerated share repurchase (~40 million shares) and invested $1.5 billion for a 34% stake in MiRus and an exclusive option on its TAVR business. Boston Scientific also highlighted positive clinical data for FARAPULSE and SEISMIQ technologies and received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter. Full-year 2026 guidance is for net sales growth of 5.5–6.5% reported and adjusted EPS of $3.28–$3.32; Q3 2026 net sales growth is guided to 3–5% with adjusted EPS of $0.80–$0.82.
Boston Scientific (NYSE: BSX) reported that the pivotal FRACTURE IDE trial of the SEISMIQ 4CE Coronary IVL Catheter in 420 patients with severe calcified CAD met its primary safety and effectiveness endpoints.
Freedom from 30-day MACE reached 93.3%, procedural success 93.7%, with 100% stent delivery and 94.2% average stent expansion.
Boston Scientific (NYSE: BSX) entered a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank under its $5 billion authorization. The company will initially receive about 30.4 million shares, with final settlement by June 30, 2026, and expects a $0.02 boost to full-year 2026 adjusted EPS. After completion, $3 billion will remain available under the repurchase authorization.
Boston Scientific (NYSE: BSX) agreed to invest $1.5 billion for an approximately 34% stake in MiRus, gaining an exclusive option to acquire its SIEGEL balloon-expandable TAVR system. The nickel-free valve uses a proprietary rhenium alloy and is being studied in the STAR pivotal trial in up to 1,025 patients.
Boston Scientific may later acquire 100% of the MiRus TAVR business through additional cash payments totaling $3 billion, plus potential sales-based and valve-asset payments. The company expects the 2026 earnings per share impact to be immaterial. The SIEGEL TAVR system remains investigational and not yet approved.
Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, up 15.6% year-over-year, with thrombectomy revenue $253.9 million (+12.1%) and embolization & access $120.8 million (+23.8%). Gross margin was 67.6%. Operating expenses were $215.2 million (R&D $22.4M; SG&A $192.8M, including $9.4M acquisition-related expenses). Income from operations was $38.2 million and net income $32.6 million. Given the pending acquisition by Boston Scientific (NYSE: BSX), the company will not provide full-year 2026 guidance or host an earnings call.
Boston Scientific (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and Dr. Janar Sathananthan in a 50-minute Q&A at ~8:00 a.m. ET. The company will webcast its Q2 2026 earnings call on July 29, 2026 at 8:00 a.m. ET, hosted by Mike Mahoney and CFO Jon Monson. A news release with Q2 results will be issued prior to the call, and live webcasts plus replays will be available at the company's investor site approximately one hour after each event.
Boston Scientific (NYSE: BSX) presented multiple late-breaking clinical results at Heart Rhythm 2026 highlighting FARAPULSE PFA and WATCHMAN LAAC technologies. Key outcomes: AVANT GUARD showed PFA superiority over anti-arrhythmic drugs (56.0% vs 30.1% primary effectiveness at 12 months); PFA safety MAE 5.1%. Feasibility and real-world cohorts reported high PVI durability (up to 96.4%) and procedural success for combined PFA+WATCHMAN procedures.
Long-term and subgroup data showed WATCHMAN reduced non-procedural bleeding versus NOACs and lower stroke rates versus control in ASAP-TOO, though some studies had enrollment or sample-size limits.
Boston Scientific (NYSE: BSX) reported Q1 2026 net sales of $5.203 billion, up 11.6% reported and 9.4% operational/organic versus prior year. GAAP net income was $1.341 billion ($0.90 EPS); adjusted EPS was $0.80. The company reported broad segment and regional growth, clinical trial wins, a China approval, an FDA 510(k) clearance and the acquisition of Valencia Technologies.